Literature DB >> 31166605

Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation.

Diego Bagnasco1, Francesco Menzella2, Marco Caminati3, Cristiano Caruso4, Giuseppe Guida5, Marco Bonavia6, Annamaria Riccio1, Manlio Milanese7, Andrea Manfredi1, Gianenrico Senna3, Giovanni Passalacqua1.   

Abstract

Entities:  

Year:  2019        PMID： 31166605     DOI： 10.1111/all.13937

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  9 in total

1.  Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.

Authors:  Emily O'Reilly; Deborah Casey; Hisham Ibrahim; Alice McGrath; Tomás McHugh; Punitha Vairamani; Jill Murphy; Barry Plant; Desmond M Murphy
Journal:  J Asthma Allergy       Date:  2022-07-11

2.  Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.

Authors:  Diego Bagnasco; Massimiliano Povero; Lorenzo Pradelli; Luisa Brussino; Giovanni Rolla; Marco Caminati; Francesco Menzella; Enrico Heffler; Giorgio Walter Canonica; Pierluigi Paggiaro; Gianenrico Senna; Manlio Milanese; Carlo Lombardi; Caterina Bucca; Andrea Manfredi; Rikki Frank Canevari; Giovanni Passalacqua
Journal:  World Allergy Organ J       Date:  2021-01-27       Impact factor: 4.084

3.  Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.

Authors:  Giovanna Elisiana Carpagnano; Emanuela Resta; Massimiliano Povero; Corrado Pelaia; Mariella D'Amato; Nunzio Crimi; Nicola Scichilone; Giulia Scioscia; Onofrio Resta; Cecilia Calabrese; Girolamo Pelaia; Maria Pia Foschino Barbaro
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

Review 4.  Specific Therapy for T2 Asthma.

Authors:  Diego Bagnasco; Elisa Testino; Stefania Nicola; Laura Melissari; Maria Russo; Rikki Frank Canevari; Luisa Brussino; Giovanni Passalacqua
Journal:  J Pers Med       Date:  2022-04-07

5.  Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Authors:  Cristiano Caruso; Paolo Cameli; Elena Altieri; Maria Aliani; Pietro Bracciale; Luisa Brussino; Maria Filomena Caiaffa; Giorgio Walter Canonica; Stefano Centanni; Maria D'Amato; Stefano Del Giacco; Fausto De Michele; Elide Anna Pastorello; Girolamo Pelaia; Paola Rogliani; Micaela Romagnoli; Pietro Schino; Marco Caminati; Alessandra Vultaggio; Alessandro Zullo; Sara Rizzoli; Silvia Boarino; Gianfranco Vitiello; Francesco Menzella; Fabiano Di Marco
Journal:  Front Med (Lausanne)       Date:  2022-09-02

6.  Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports.

Authors:  Lombardi Carlo; Menzella Francesco; Passalacqua Giovanni
Journal:  Respir Med Case Rep       Date:  2019-11-19

Review 7.  Severe Asthma and Biological Therapy: When, Which, and for Whom.

Authors:  Paola Rogliani; Luigino Calzetta; Maria Gabriella Matera; Rossella Laitano; Beatrice Ludovica Ritondo; Nicola A Hanania; Mario Cazzola
Journal:  Pulm Ther       Date:  2019-12-26

8.  Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

Authors:  Giovanna Elisiana Carpagnano; Corrado Pelaia; Maria D'Amato; Nunzio Crimi; Nicola Scichilone; Giulia Scioscia; Onofrio Resta; Cecilia Calabrese; Girolamo Pelaia; Carla Maria Irene Quarato; Maria Pia Foschino Barbaro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

9.  Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.

Authors:  Corrado Pelaia; Claudia Crimi; Santi Nolasco; Giovanna Elisiana Carpagnano; Raffaele Brancaccio; Enrico Buonamico; Raffaele Campisi; Claudia Gagliani; Vincenzo Patella; Girolamo Pelaia; Giuseppe Valenti; Nunzio Crimi
Journal:  Biomedicines       Date:  2021-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.